Merck KGaA to Acquire Bio-Techne in $17B Deal to Expand Life Sciences Leadership
- Jul 1
- 1 min read
Darmstadt, Germany, June 25, 2026 (PR Newswire) -- Merck KGaA has agreed to acquire Bio-Techne in a transaction valued at approximately $17 billion. The acquisition is intended to strengthen Merck’s position in rapidly growing life sciences markets by adding complementary technologies and capabilities. The deal supports the company’s strategy to expand its global presence and enhance its portfolio of research and bioprocessing solutions.
Read full article here.






















Comments